BioMarin Pharmaceutical (NASDAQ:BMRN) Rating Increased to Strong-Buy at Citigroup

Posted by Brian Himes on May 20th, 2026

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) was upgraded by stock analysts at Citigroup to a “strong-buy” rating in a research report issued on Monday,Zacks.com reports.

Other equities research analysts also recently issued research reports about the company. Canaccord Genuity Group increased their target price on BioMarin Pharmaceutical from $104.00 to $116.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Oppenheimer lowered their price objective on BioMarin Pharmaceutical from $98.00 to $95.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 24th. Barclays increased their price objective on BioMarin Pharmaceutical from $80.00 to $105.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 3rd. Jefferies Financial Group reiterated a “buy” rating and issued a $103.00 price objective on shares of BioMarin Pharmaceutical in a research report on Thursday, March 12th. Finally, Loop Capital set a $105.00 price objective on BioMarin Pharmaceutical in a research report on Monday, March 2nd. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $88.88.

View Our Latest Report on BMRN

BioMarin Pharmaceutical Trading Up 0.3%

NASDAQ:BMRN opened at $49.84 on Monday. The company has a market cap of $9.63 billion, a P/E ratio of 36.38, a P/E/G ratio of 0.37 and a beta of 0.23. The stock’s fifty day moving average price is $55.04 and its two-hundred day moving average price is $56.27. BioMarin Pharmaceutical has a 1 year low of $49.26 and a 1 year high of $66.28. The company has a debt-to-equity ratio of 0.23, a current ratio of 5.81 and a quick ratio of 4.20.

Insider Transactions at BioMarin Pharmaceutical

In other BioMarin Pharmaceutical news, EVP Charles Greg Guyer sold 16,486 shares of the firm’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $60.46, for a total transaction of $996,743.56. Following the sale, the executive vice president owned 79,953 shares in the company, valued at $4,833,958.38. This trade represents a 17.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Gregory R. Friberg sold 3,281 shares of the firm’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $53.85, for a total value of $176,681.85. Following the sale, the executive vice president owned 51,818 shares in the company, valued at $2,790,399.30. The trade was a 5.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 26,093 shares of company stock worth $1,555,389 in the last 90 days. Company insiders own 0.85% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of BMRN. Norges Bank purchased a new position in BioMarin Pharmaceutical during the 4th quarter valued at about $447,572,000. Vestal Point Capital LP boosted its position in BioMarin Pharmaceutical by 261.4% during the 4th quarter. Vestal Point Capital LP now owns 3,000,000 shares of the biotechnology company’s stock valued at $178,290,000 after acquiring an additional 2,170,000 shares in the last quarter. Capital Research Global Investors boosted its position in BioMarin Pharmaceutical by 547.5% during the 3rd quarter. Capital Research Global Investors now owns 2,537,596 shares of the biotechnology company’s stock valued at $137,436,000 after acquiring an additional 2,145,717 shares in the last quarter. Viking Global Investors LP boosted its position in BioMarin Pharmaceutical by 13.8% during the 2nd quarter. Viking Global Investors LP now owns 12,288,611 shares of the biotechnology company’s stock valued at $675,505,000 after acquiring an additional 1,488,552 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in BioMarin Pharmaceutical by 48.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,321,754 shares of the biotechnology company’s stock valued at $197,405,000 after acquiring an additional 1,076,568 shares in the last quarter. Hedge funds and other institutional investors own 98.71% of the company’s stock.

BioMarin Pharmaceutical Company Profile

(Get Free Report)

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.